ORKAMBI (lumacaftor and ivacaftor)
**Product type:** Human Prescription Drug
**Active ingredient:** IVACAFTOR; LUMACAFTOR
**Strength:** 188; 150 mg/1; mg/1
**Dosage form:** Granule
**Route:** Oral
**Labeler:** Vertex Pharmaceuticals Incorporated
**Marketing category:** NDA (NDA211358)
**Pharmacologic class:** Chloride Channel Activation Potentiators [MoA], Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC], Cytochrome P450 2B6 Inducers [MoA], Cytochrome P450 2C19 Inducers [MoA], Cytochrome P450 2C8 Inducers [MoA], Cytochrome P450 2C8 Inhibitors [MoA], Cytochrome P450 2C9 Inducers [MoA], Cytochrome P450 2C9 Inhibitors [MoA], Cytochrome P450 2C9 Inhibitors [MoA], Cytochrome P450 3A Inducers [MoA], Cytochrome P450 3A Inhibitors [MoA], P-Glycoprotein Inducers [MoA], P-Glycoprotein Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA]
/api/v1/systems/ndc_fda/nodes/51167-500Hierarchy Explorer
Cross-system equivalences0
No cross-system equivalences mapped for this node.